Clinical trial
Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma - a Phase II Clinical Trial.
NCT00399867 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma - a Phase II Clinical Trial.
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- April 30, 2007
- Enrollment
- 30
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.